NO20074267L - Konjugater av biologisk aktive proteiner som har en modifisert in vivo halveringstid - Google Patents

Konjugater av biologisk aktive proteiner som har en modifisert in vivo halveringstid

Info

Publication number
NO20074267L
NO20074267L NO20074267A NO20074267A NO20074267L NO 20074267 L NO20074267 L NO 20074267L NO 20074267 A NO20074267 A NO 20074267A NO 20074267 A NO20074267 A NO 20074267A NO 20074267 L NO20074267 L NO 20074267L
Authority
NO
Norway
Prior art keywords
biologically active
life
modified
polypeptide
conjugates
Prior art date
Application number
NO20074267A
Other languages
English (en)
Inventor
Marc Besman
Stewart Chipman
David Leung
Original Assignee
Cell Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Therapeutics Inc filed Critical Cell Therapeutics Inc
Publication of NO20074267L publication Critical patent/NO20074267L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Sammendrag Angitt er biologisk aktive proteinkonjugater som omfatter et biologisk aktivt polypeptid koblet via en peptidbinding til et polypeptid omfattende fra 2 til omkring 500 enheter av et repeterende peptidmotiv, hvor det biologisk aktive proteinkonjugatet viser en modifisert plasmahalveringstid sammenlignet med den indre halveringstiden av det ikke-konjugerte biologisk aktive polypeptidet eller proteinet. Også angitt er fremgangsmåter for å lage og anvende de konjugerte proteinene, så vel som fremgangsmåter for å bestemme hvorvidt et gitt konjugat viser en modifisert halveringstid relativt til den indre halveringstiden av det ikke-konjugerte polypeptidet.
NO20074267A 2005-01-25 2007-08-21 Konjugater av biologisk aktive proteiner som har en modifisert in vivo halveringstid NO20074267L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64711905P 2005-01-25 2005-01-25
US71258505P 2005-08-30 2005-08-30
PCT/US2006/002501 WO2006081249A2 (en) 2005-01-25 2006-01-25 Conjugates of biologically active proteins having a modified in vivo half-life

Publications (1)

Publication Number Publication Date
NO20074267L true NO20074267L (no) 2007-09-28

Family

ID=36644921

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074267A NO20074267L (no) 2005-01-25 2007-08-21 Konjugater av biologisk aktive proteiner som har en modifisert in vivo halveringstid

Country Status (14)

Country Link
US (2) US8129348B2 (no)
EP (1) EP1841787A2 (no)
JP (2) JP5735194B2 (no)
KR (1) KR101608083B1 (no)
CN (1) CN103172747A (no)
AU (1) AU2006208199B2 (no)
BR (1) BRPI0606934A2 (no)
CA (1) CA2595695A1 (no)
IL (1) IL184763A (no)
MX (1) MX2007008982A (no)
NO (1) NO20074267L (no)
NZ (1) NZ556726A (no)
RU (1) RU2007132188A (no)
WO (1) WO2006081249A2 (no)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006081249A2 (en) * 2005-01-25 2006-08-03 Cell Therapeutics, Inc. Conjugates of biologically active proteins having a modified in vivo half-life
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
EP1996220B2 (en) † 2006-03-06 2023-08-16 Amunix Operating Inc. Unstructured recombinant polymers and uses thereof
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
DK1996220T4 (da) † 2006-03-06 2023-11-13 Amunix Operating Inc Ustrukturerede rekombinante polymerer og anvendelsen deraf
EP2009103A1 (en) * 2007-03-16 2008-12-31 Ebewe Pharma Ges.m.b.H. Nfg. KG Neurotrophic peptides
US8592374B2 (en) 2007-03-16 2013-11-26 Research Foundation For Mental Hygiene, Inc. Neurotrophic peptides
DK2173890T3 (da) 2007-06-21 2011-06-27 Univ Muenchen Tech Biologisk aktive proteiner med forhøjet stabilitet in vivo og/eller in vitro
AU2013203326B2 (en) * 2007-06-21 2013-08-01 Technische Universitat Munchen Biological active proteins having increased in vivo and/or in vitro stability
JP2010536341A (ja) 2007-08-15 2010-12-02 アムニクス， インコーポレイテッド 生物学的に活性なポリペプチドの特性を改変するための組成物および方法
CA2697951A1 (en) * 2007-08-30 2009-03-05 University Of Waterloo Amino acid pairing-based self assembling peptides and methods
CN103864895A (zh) 2008-12-29 2014-06-18 隆萨布莱纳公司 制备比伐卢定的方法
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
LT2393828T (lt) 2009-02-03 2017-01-25 Amunix Operating Inc. Prailginti rekombinantiniai polipeptidai ir juos apimančios kompozicijos
JP5499296B2 (ja) * 2009-02-03 2014-05-21 国立大学法人東京農工大学 細胞の吸着を制御可能なポリペプチド
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
AU2010258898B8 (en) 2009-06-08 2015-02-05 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
EP2470559B1 (en) 2009-08-24 2017-03-22 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
WO2011123830A2 (en) 2010-04-02 2011-10-06 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
PL2571510T3 (pl) 2010-05-21 2019-03-29 Xl-Protein Gmbh Biosyntetyczne polipeptydy prolinowo/alaninowe o strukturze kłębka statystycznego i ich zastosowania
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9783602B2 (en) 2010-12-01 2017-10-10 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US20140323402A1 (en) 2011-08-12 2014-10-30 Ascendis Phama A/S Protein Carrier-Linked Prodrugs
RS63870B1 (sr) 2012-02-15 2023-01-31 Bioverativ Therapeutics Inc Sastavi faktora viii i postupci za pravljenje i upotrebu istih
WO2013123457A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
CA2865578C (en) 2012-02-27 2023-01-17 Amunix Operating Inc. Xten conjugate compositions and methods of making same
WO2013172967A1 (en) 2012-05-17 2013-11-21 Extend Biosciences, Inc Carriers for improved drug delivery
RU2019143431A (ru) * 2012-11-01 2020-04-28 Фэктор Байосайенс Инк. Способы и продукты для экспрессии белков в клетках
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
CA2964463C (en) 2014-10-22 2024-02-13 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
EP3543339A1 (en) 2015-02-13 2019-09-25 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
CN104988107B (zh) * 2015-05-19 2018-06-08 中国农业科学院兰州兽医研究所 一种高效表达口蹄疫病毒抗原基因的重组乳酸杆菌及其制备方法和应用
CN107743494B (zh) * 2015-06-02 2022-04-29 诺和诺德股份有限公司 具有极性重组延伸体的胰岛素
UA126016C2 (uk) 2015-08-03 2022-08-03 Біовератів Терапеутікс Інк. Злитий білок фактора іх
TWI744247B (zh) 2015-08-28 2021-11-01 美商亞穆尼克斯製藥公司 嵌合多肽組合體以及其製備及使用方法
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
CN116115629A (zh) 2016-08-17 2023-05-16 菲克特生物科学股份有限公司 核酸产品及其施用方法
US11198725B2 (en) 2017-01-30 2021-12-14 Alexion Pharmaceuticals, Inc. Monovalent anti-properdin antibodies and antibody fragments
JP2020513019A (ja) 2017-04-05 2020-04-30 ノヴォ ノルディスク アー／エス オリゴマー伸長インスリン−Ｆｃコンジュゲート
US12060424B2 (en) 2017-12-21 2024-08-13 Amunix Pharmaceuticals, Inc. Release segments and binding compositions comprising same
TW202015723A (zh) 2018-05-18 2020-05-01 美商百歐維拉提夫治療公司 治療ａ型血友病的方法
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
CN114641484B (zh) * 2019-11-05 2024-08-09 国立大学法人京都大学 肽、组合物及治疗、预防或改善心境障碍的方法
CN112608366B (zh) * 2020-12-31 2024-08-30 中国药科大学 超正电荷聚多肽及其制备方法、应用
CN113480667B (zh) * 2021-08-17 2023-03-28 长春萤火虫生物科技有限公司 一种人粒细胞集落刺激因子突变体重组融合蛋白及其制备方法和应用
WO2024128079A1 (ja) * 2022-12-16 2024-06-20 東亞合成株式会社 合成ペプチド及び構築物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JP3045539B2 (ja) * 1989-02-21 2000-05-29 ワシントン ユニバーシティ 改変型生殖ホルモン
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6455678B1 (en) 1996-04-26 2002-09-24 Amcell Corporation Human hematopoietic stem and progenitor cell antigen
CN1240479A (zh) * 1996-07-09 2000-01-05 安姆根有限公司 截短的可溶性肿瘤坏死因子i－型和ii－型受体
EP0979102A4 (en) 1997-04-30 2005-11-23 Enzon Inc DETAILED POLYPEPTIDE MODIFIED BY POLYALKYLENE OXIDE
AU3210100A (en) 1999-01-19 2000-08-01 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
US6831158B2 (en) 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
WO2002002597A2 (en) * 2000-06-30 2002-01-10 Maxygen Aps Peptide extended glycosylated polypeptides
CA2513287A1 (en) 2002-01-14 2003-07-17 William Herman Multispecific binding molecules
JP4503606B2 (ja) 2004-07-06 2010-07-14 株式会社エヌ・ティ・ティ・ドコモ メッセージ送信システム及びメッセージ送信方法
DE102004049479A1 (de) 2004-10-11 2006-04-13 Scil Proteins Gmbh Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie
WO2006081249A2 (en) * 2005-01-25 2006-08-03 Cell Therapeutics, Inc. Conjugates of biologically active proteins having a modified in vivo half-life
CN101111516B (zh) * 2005-01-25 2013-02-27 细胞治疗学公司 体内半衰期改变的生物活性蛋白质偶联物

Also Published As

Publication number Publication date
EP1841787A2 (en) 2007-10-10
NZ556726A (en) 2011-04-29
CA2595695A1 (en) 2006-08-03
US8129348B2 (en) 2012-03-06
WO2006081249A2 (en) 2006-08-03
US8748577B2 (en) 2014-06-10
AU2006208199A1 (en) 2006-08-03
BRPI0606934A2 (pt) 2017-07-11
WO2006081249A3 (en) 2007-02-01
US20090298762A1 (en) 2009-12-03
JP2013100292A (ja) 2013-05-23
RU2007132188A (ru) 2009-03-10
WO2006081249A9 (en) 2007-07-26
KR20070119622A (ko) 2007-12-20
IL184763A (en) 2013-05-30
US20120252717A1 (en) 2012-10-04
CN103172747A (zh) 2013-06-26
WO2006081249A8 (en) 2007-09-13
JP2008528002A (ja) 2008-07-31
KR101608083B1 (ko) 2016-04-01
AU2006208199B2 (en) 2012-06-07
JP5735194B2 (ja) 2015-06-17
IL184763A0 (en) 2007-12-03
MX2007008982A (es) 2007-12-06

Similar Documents

Publication Publication Date Title
NO20074267L (no) Konjugater av biologisk aktive proteiner som har en modifisert in vivo halveringstid
CY1119243T1 (el) Φαρμακοτεχνικες μορφες ανταγωνιστη του vegf
ES2397852T3 (es) Antagonistas y conjugados de péptidos CGRP
WO2006074467A3 (en) Glycopegylated granulocyte colony stimulating factor
AU2012255119B2 (en) Improved peptide pharmaceuticals for insulin resistance
WO2005055950A3 (en) Glycopegylated factor ix
NO20080970L (no) Glykopegylert faktor VII og faktor VIIA
SI1180121T1 (en) Long lasting insulinotropic peptides
RS54215B1 (en) COMPOSITIONS AND PROCEDURES FOR DIAGNOSIS AND TREATMENT OF CANCER
WO2005055946A3 (en) Glycopegylated granulocyte colony stimulating factor
WO2005056760A3 (en) Glycopegylated follicle stimulating hormone
BRPI0717505B8 (pt) conjugado de peptídeo e formulação farmacêutica
NO20082716L (no) Sammensetninger og fremgangsmater for fremstilling av en sammensetning
UA96916C2 (ru) Конъюгат полипептида и синтетически сульфатованого пентасахарида, фармацевтическая композиция на его основе
DK1329458T5 (da) Peptider som sænker blodglucoseniveauer
WO2006113681A3 (en) Plant-derived elastin binding protein ligands and methods of using the same
SE9901379D0 (sv) Receptor structures
CY1117104T1 (el) Διαλυτες γλυκοσαμινογλυκανασες και μεθοδοι παρασκευης και χρησης των διαλυτων γλυκοσαμινογλυκανασων
MXPA03011094A (es) Citotoxinas, profarmacos, ligadores, y estabilizadores utiles para ello.
WO2006127910A3 (en) Glycopegylated erythropoietin formulations
CY1113299T1 (el) Πολυπεπτιδια απροτινινης για τη μεταφορα μιας ενωσης μεσα στον αιματοεγκεφαλικο φραγμο
MX2007013626A (es) Anticuerpos dirigidos contra el peptido beta amiloide y procedimientos que usan los mismos.
WO2007067979A3 (en) Targeting vector-phospholipid conjugates
WO2003049684A3 (en) Pseudo-antibody constructs
WO2006119035A3 (en) Vegf variants

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application